Vera Therapeutics, Inc.
VERA
$21.71
-$0.32-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 91.79% | 72.35% | 29.55% | 14.19% | 8.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.71% | 63.87% | 33.82% | 4.63% | -3.11% |
| Operating Income | -89.71% | -63.87% | -33.82% | -4.63% | 3.11% |
| Income Before Tax | -86.06% | -58.50% | -30.75% | -0.47% | 7.58% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -86.06% | -58.50% | -30.75% | -0.47% | 7.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.06% | -58.50% | -30.75% | -0.47% | 7.58% |
| EBIT | -89.71% | -63.87% | -33.82% | -4.63% | 3.11% |
| EBITDA | -89.08% | -135.79% | -87.32% | -44.31% | -37.33% |
| EPS Basic | -46.52% | -19.86% | 9.65% | 33.85% | 40.34% |
| Normalized Basic EPS | -46.56% | -19.89% | 9.55% | 33.65% | 40.02% |
| EPS Diluted | -46.52% | -19.86% | 9.65% | 33.85% | 40.34% |
| Normalized Diluted EPS | -46.56% | -19.89% | 9.55% | 33.65% | 40.02% |
| Average Basic Shares Outstanding | 27.13% | 29.60% | 33.13% | 42.11% | 53.78% |
| Average Diluted Shares Outstanding | 27.13% | 29.60% | 33.13% | 42.11% | 53.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |